ArticleJournal of general internal medicine2011
Chronic kidney disease and the risk of end-stage renal disease versus death.
Article in Journal of general internal medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07547878 (A Pilot Randomized Clinical Trial to Assess Feasibility, Safety, and Efficacy of Rapid, Simultaneous Therapy Initiation in Chronic Kidney Disease and Type 2 Diabetes), which is not on this map. Cited by 127 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Pilot Randomized Clinical Trial to Assess Feasibility, Safety, and Efficacy of Rapid, Simultaneous Therapy Initiation in Chronic Kidney Disease and Type 2 Diabetes: RAPID-CKD
Who cites it
127 citing papers in PubMed, 3 syntheses or guidelines pooled it, 253 citations in OpenAlex.
- HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.The Cochrane database of systematic reviews · 2023Pooled it
- Pooled it
- Prevention of chronic kidney disease and subsequent effect on mortality: a systematic review and meta-analysis.PloS one · 2013Pooled it
- Comparing survival in patients with chronic kidney disease across three countries - Results from the study of heart and renal protection-extended review.Nephrology (Carlton, Vic.) · 2023Trial
- Functional training added to intradialytic cycling lowers low-density lipoprotein cholesterol and improves dialysis adequacy: a randomized controlled trial.BMC nephrology · 2020Trial
- A randomized, multicenter, open-label, blinded end point trial comparing the effects of spironolactone to chlorthalidone on left ventricular mass in patients with early-stage chronic kidney disease: Rationale and design of the SPIRO-CKD trial.American heart journal · 2017Trial
- Long-term mortality and risk factors for development of end-stage renal disease in critically ill patients with and without chronic kidney disease.Critical care (London, England) · 2015Trial
- Trial
- Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease.Clinical journal of the American Society of Nephrology : CJASN · 2012Trial
- Article
- [Surrogate markers in chronic kidney disease : Estimated glomerular filtration rate and albuminuria in clinical practice and in studies].Innere Medizin (Heidelberg, Germany) · 2026Review
- Planning of kidney replacement therapy in advanced CKD using the KFRE formula in a Spanish multicenter cohort.Clinical kidney journal · 2026Article
- Refining the Cardiovascular-Kidney-Metabolic Staging System for Improved Risk Stratification of Chronic Kidney Disease Progression in Type 2 Diabetes.Circulation reports · 2026Article
- Multimorbidity patterns and the subsequent risk of albuminuria: findings from the Stockholm Creatinine Measurements (SCREAM) project.BMC medicine · 2026Article
- Sex Differences in Dementia and Mild Cognitive Impairment in Nondialysis CKD.Clinical journal of the American Society of Nephrology : CJASN · 2026Article
- Kidney and Survival Outcomes with Semaglutide by CKD Severity in the FLOW Trial.Clinical journal of the American Society of Nephrology : CJASN · 2026Article
- Monocyte-to-HDL ratio (MHR) is associated with overall and renal mortality in community-dwelling older individuals with chronic kidney disease (CKD).Journal of translational medicine · 2026Article
- Using the Difference Between Estimated Glomerular Filtration Rate by Cystatin C and Creatinine to Improve Mortality Risk Prediction in Elderly Patients With CKD in the HUNT Study.Kidney medicine · 2026Article
- A Real-World Cohort Study of the Risks of Kidney Failure and Death in Diabetes.Clinical journal of the American Society of Nephrology : CJASN · 2026Article
- Article
67 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
10 authors at 8 institutions in 1 country.
Funding
Abstract
backgroundAmong older adults with chronic kidney disease (CKD), the comparative event rates of end-stage renal disease (ESRD) and cause-specific death are unknown.
objectiveTo compare the rates of ESRD, cardiovascular and non-cardiovascular death and examine risk factors for ESRD and all-cause mortality in Cardiovascular Health Study (CHS) participants.
designThe CHS is a longitudinal cohort study of community-dwelling adults aged 65 years and older.
participants1,268 participants with an estimated glomerular filtration rate (eGFR) < 60 ml/min per 1.73 m(2) were followed until the time of first event (ESRD, cardiovascular or non-cardiovascular death) or until March 31, 2003. MAIN MEASURES: The outcomes were ESRD, cardiovascular- and non-cardiovascular death. Rates of each event were calculated, and a Cox Proportional Hazards Model with a competing risk framework was used to examine risk factors for ESRD as compared with death. Predictors included age, gender, race, BMI, hypertension, diabetes, cardiovascular disease, heart failure, tobacco use, eGFR, and total cholesterol. KEY
resultsDuring 9.7 years of follow-up, 5% of the cohort progressed to ESRD, and 61% of the cohort died. The rate (per 100 person-years) was 0.5 for ESRD and 6.8 for all-cause mortality (3.0 for cardiovascular and 3.8 for non-cardiovascular mortality). In the competing risk framework, lower eGFR, male gender, African-American race, and higher BMI were associated with an increased risk of ESRD.
conclusionsOlder adults with CKD are 13-fold more likely to die from any cause than progress to ESRD and are 6-fold more likely to die from cardiovascular causes than develop ESRD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.